Sodium fusidate (fusidic acid)

Dose in renal impairment

No dose adjustment is required in renal impairment. Not dialysed.

Use in hepatic impairment

• Use with caution and liver function should be monitored if used in patients with hepatic dysfunction or in patients taking potentially hepatotoxic drugs
• Use with caution in patients with biliary disease and biliary tract obstruction

Discuss with pharmacy.

• There is an increased risk of myopathy and rhabdomyolysis when sodium fusidate is given with statins. Withhold statins whilst patients are taking sodium fusidate. Statin therapy can be re-started 7 days after the last dose of sodium fusidate is taken.
• Sodium fusidate interacts with many drugs. Contact a pharmacist for further advice.
• Dose of tablets (as sodium fusidate) and dose of suspension (as fusidic acid) are not interchangeable. Contact a pharmacist for further advice.

1. Summary of Product Characteristics (SPC) for Fucidin Tablets. Accessed via www.medicines.org.uk 15/1/19. Last updated 23/8/18
2. The Renal Drug Database. Fusidic Acid. Accessed via renaldrugdatabase.com 26/03/18. Last updated 22/02/18
3. BNF online accessed via www.medicinescomplete.com 14/1/19; last updated 16/6/17

4. MHRA. Drug Safety update (December 2014) Systemic fusidic acid and interaction with statins. Accessed at https://www.gov.uk/drug-safety-update/systemic-fusidic-acid-and-interaction-with-statins